Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis

Sarilumab, an IL-6 receptor antagonist, is a first-line biologic disease-modifying anti-rheumatic drug for rheumatoid arthritis. The identification of genetic biomarkers as predictors of response to sarilumab ...

Source: Arthritis Research and Therapy - November 24, 2023 Category: Rheumatology Authors: Luis Sainz, Pau Riera, Patricia Moya, Sara Bernal, Jordi Casademont, Cesar D íaz-Torné, Ana Milena Millán, Hye Sang Park, Adriana Lasa and Hector Corominas Tags: Research Source Type: research